PF-06835919 (PF06835919) is a novel and potent ketohexokinase (KHK) inhibitor with IC50s of 8.4 nM and 66 nM for KHK-C and KHK-A, respectively. It has the potential to be used for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose. As a first-in-class ketohexokinase (KHK) inhibitor, PF-06835919 showed reversal of such metabolic disorders in preclinical models and clinical studies, and is under clinical development for the potential treatment of NASH. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders.

纯度：≥98%

CAS：2102501-84-6